GlassScriptPhysician profile
Daryush Parsa
NPI 1417011594
$6,062.13
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
See the full distribution for Geriatric Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,880 · 2020: $300 · 2021: $951 · 2022: $1,088 · 2023: $902 · 2024: $941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,843.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,017.90 | 2020-2024 | Calquence, Enhertu, Tagrisso |
| Lilly USA, LLC | $968.75 | 2021-2024 | Verzenio, Jaypirca |
| Celgene Corporation | $460.34 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $459.70 | 2019-2024 | Lynparza, Keytruda |
| Regeneron Healthcare Solutions, INC. | $248.36 | 2021-2023 | Libtayo |
| Amgen INC. | $242.08 | 2019-2021 | |
| Genzyme Corporation | $231.92 | 2019 | |
| Eisai INC. | $228.28 | 2019-2022 | |
| Genentech USA, INC. | $209.59 | 2019-2023 | Tecentriq |
| Tesaro, INC. | $205.81 | 2019 | |
| Incyte Corporation | $125.00 | 2019 | |
| Beigene USA, INC. | $125.00 | 2022 | |
| Seagen INC. | $122.83 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.36 | 2020 | |
| Alexion Pharmaceuticals, INC. | $121.22 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $115.57 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $115.12 | 2019-2022 | |
| Glaxosmithkline, LLC. | $104.83 | 2021 | |
| Ge Healthcare | $103.00 | 2022 | |
| Array Biopharma INC | $101.72 | 2019 | |
| Clovis Oncology, INC. | $100.21 | 2019 | |
| Genmab U.S., INC. | $98.43 | 2024 | Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $98.21 | 2019 | |
| Daiichi Sankyo INC. | $95.43 | 2019 | |
| Progenics Pharmaceuticals, INC. | $85.20 | 2023 | Pylarify |
| Sobi, INC | $70.02 | 2024 | |
| Gilead Sciences, INC. | $46.55 | 2024 | Trodelvy |
| Sun Pharmaceutical Industries INC. | $39.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daryush Parsa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.